InvestorsHub Logo
Followers 1
Posts 516
Boards Moderated 0
Alias Born 08/27/2012

Re: Sparroww post# 9521

Thursday, 06/22/2023 11:55:30 AM

Thursday, June 22, 2023 11:55:30 AM

Post# of 9558
I enjoyed reading this release https://investorhub.imagionbiosystems.com/announcements/4372071

A little too late for me as I sold my position, with a new CEO, this may be worth looking at in the future.. as usual Bob creates press release that can bore folks to sleep.. so here is a simple explanation.

Imagion Biosystems, a company dedicated to earlier cancer detection, said that they've achieved their goals for their first clinical study, the MagSense® HER2 breast cancer Phase 1 study, and are preparing to close the study by July 31, 2023.

What does this mean?

Well, they've developed this cool, new technology that can help change how we use MRI to spot cancer. It's like a special contrast agent that makes it easier to see cancer on an MRI image. Some independent experts in radiology checked out their work and agree that it's really promising!

So what's next?

With the success of this study, Imagion is now set to prepare a submission for a larger, multi-site Phase 2 trial in the U.S., which they hope to start by the end of 2023 or early 2024. But before they do that, they'll be making more of their special MagSense® HER2 imaging agent and completing some additional studies following the FDA's guidance.

They also plan to recruit a few more patients to test a new method of imaging after the cancerous nodes have been removed from the body. This might help them to correlate MRI findings with pathology in the upcoming Phase 2 study.

All this will take time and Lot$$$ of money and probably further dilution.

Good luck to all those still in the stock.